Innovations Kapital
41
7M
31
1.46
9
0.24
14
- Stages of investment
- Areas of investment
Summary
In 1994 was created Innovations Kapital, which is appeared as VC. The leading representative office of defined VC is situated in the Gu00f6teborg. The company was established in Europe in Sweden.
The top amount of exits for fund were in 2007. The fund is constantly included in less than 2 deals per year. The top activity for fund was in 2006. Deals in the range of 5 - 10 millions dollars are the general things for fund. Speaking about the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. Opposing the other organizations, this Innovations Kapital works on 8 percentage points more the average amount of lead investments.
The usual cause for the fund is to invest in rounds with 3 partakers. Despite the Innovations Kapital, startups are often financed by Tesi, Teknoinvest, TVM Capital. The meaningful sponsors for the fund in investment in the same round are Teknoinvest, TVM Capital, Northzone. In the next rounds fund is usually obtained by Teknoinvest, Industrifonden, HealthCap.
Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Sweden. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Health Care. Among the most popular portfolio startups of the fund, we may highlight Novavax AB, Ludesi, Syntensia. The fund has specific favorite in a number of founders of portfolio startups.
This organization was formed by Staffan Ingeborn. The overall number of key employees were 2.
Investor highlights
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 41
- Lead investments
- 9
- Exits
- 14
- Rounds per year
- 1.46
- Follow on index
- 0.24
- Investments by industry
- Biotechnology (15)
- Software (12)
- Health Care (11)
- Manufacturing (8)
- Electronics (5) Show 37 more
- Investments by region
-
- Sweden (18)
- United States (7)
- Denmark (6)
- Finland (4)
- Germany (1) Show 3 more
- Peak activity year
- 2006
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 22
- Avg. valuation at time of investment
- 14M
- Group Appearance index
- 0.73
- Avg. company exit year
- 12
- Avg. multiplicator
- 3.08
- Strategy success index
- 0.30
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Resistentia Pharmaceuticals | 26 Sep 2006 | Biotechnology, Health Care, Medical Device, Therapeutics | Late Stage Venture | 14M | Uppsala County, Uppsala, Sweden |
| SantoSolve | 31 Jan 2010 | Biotechnology, Health Care, Clinical Trials | Late Stage Venture | 5M | Norway, Oslo |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.